Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Evolving Concepts: Immunity In Oncology From Targets To Treatments

H. Khan, R. Gucalp, I. Shapira
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Cancer is associated with global immune suppression of the host. Malignancy-induced immune suppressive effect can be circumvented by blocking the immune checkpoint and tip the immune balance in favor of immune stimulation and unleash cytotoxic effects on cancer cells. Human antibodies directed against immune checkpoint proteins: cytotoxic T lymphocytes antigen-4 (CTLA-4) and programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), have shown therapeutic efficacy in advanced melanoma and non-small-cell lung cancer and other malignancies. Immune check point blockade antibodies lead to diminished tolerance to self and enhanced immune ability to recognize and eliminate cancer cells. As a class these agents have immune-related adverse events due to decreased ability of effector immune cells to discriminate between self and non-self. Seventy percent of patients participating in clinical trials have experienced anticancer activities and varying degrees of immune mediated dose-limiting side effects.
This paper references
10.1200/JCO.2013.31.15_SUPPL.3001
Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.
J. Powderly (2013)
PD 1 blockade reverses the suppression of melanoma antigen - specific CTL by CD 4 + CD 25 Hi regulatory T cells
F. S. Hodi (2009)
10.1073/pnas.0712237105
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. S. Hodi (2008)
10.1200/JCO.2014.32.15_SUPPL.6011
A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.
T. Seiwert (2014)
andD.Quandt, “The expression, function, and clinical relevance of B7 familymembers in cancer,”Cancer
B. Seliger (2012)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Co-inhibitorymolecules of the B7-CD28 family in the control of T-cell immunity,”Nature
L. Chen (2004)
10.1038/nm0902-1039c
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
10.1200/JCO.2009.23.4799
Final version of 2009 AJCC melanoma staging and classification.
C. Balch (2009)
10.1007/s12254-012-0019-y
Immunotherapy for nonsmall-cell lung cancer
A. Belalcazar (2012)
10.1182/blood-2007-11-123141
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.
T. Azuma (2008)
10.4049/jimmunol.173.2.945
SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1
J. Chemnitz (2004)
10.1634/theoncologist.2010-0190
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
C. Garbe (2011)
Loss of T-cell receptor ζ chain and p56lck in T-cells infiltrating human renal cell carcinoma,”Cancer
J. H. Finke (1993)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
10.1158/1078-0432.CCR-06-2599
PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma
R. H. Thompson (2007)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1007/s00262-012-1293-6
The expression, function, and clinical relevance of B7 family members in cancer
B. Seliger (2012)
10.3747/CO.V14I1.109
Single-agent interleukin-2 in the treatment of metastatic melanoma
T. Petrella (2007)
10.1158/0008-5472.CAN-12-2606
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.
C. Badoual (2013)
BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC)
(2013)
10.1200/JCO.2009.26.7609
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
J. Brahmer (2010)
10.1084/jem.20090681
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
Cameron S. Brandt (2009)
10.1016/j.coi.2011.12.009
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
Suzanne L. Topalian (2012)
10.1016/S0065-3527(08)60074-3
Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine.
A. Arvin (1996)
10.1200/JCO.2013.31.15_SUPPL.9010
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).
O. Hamid (2013)
10.1200/JCO.2005.01.109
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
A. Ribas (2005)
Survival and longterm follow-up of the phase I trial of nivolumab (Anti-PD- 1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC)
J. R. Brahmer (2013)
BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
S. Strome (2003)
10.1200/JCO.1996.14.1.7
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
J. Kirkwood (1996)
10.4049/jimmunol.171.3.1232
l-Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes1
P. Rodriguez (2003)
receptor ζ chain is sufficient to couple to receptor - associated signal transduction pathways
P. C. Rodriguez (1991)
10.1038/70932
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
H. Dong (1999)
10.1158/0008-5472.CAN-12-2409
ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.
J. Faget (2012)
10.1016/S1470-2045(12)70007-4
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
A. V. D. van den Eertwegh (2012)
10.1056/NEJMoa1200694
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
10.1158/1078-0432.CCR-12-2625
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
E. Lipson (2012)
Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer
E Garon (2013)
10.1002/IJC.2910630210
Variable expression of CD3‐ζ chain in tumor‐infiltrating lymphocytes (TIL) derived from renal‐cell carcinoma: Relationship with til phenotype and function
E. Tartour (1995)
10.1182/BLOOD.V88.1.236.BLOODJOURNAL881236
T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28.
C. Renner (1996)
10.1200/JCO.2014.32.15_SUPPL.3002
Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.
N. Segal (2014)
10.1007/s12105-012-0406-z
B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma
O. Ukpo (2012)
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma.
H. Nakagomi (1993)
10.1200/JCO.2014.32.15_SUPPL.3018
Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers.
Y. Lou (2014)
10.1126/SCIENCE.1465616
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice.
H. Mizoguchi (1992)
10.1200/JCO.2013.31.15_SUPPL.3016
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
Joseph F. Grosso (2013)
10.1093/intimm/dxp072
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.
W. Wang (2009)
10.2174/156652307782793504
Lung cancer vaccines.
R. Eager (2007)
10.1038/nature04444
Restoring function in exhausted CD8 T cells during chronic viral infection
D. Barber (2006)
10.1200/JCO.2014.32.15_SUPPL.4504
Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
H. Hammers (2014)
10.1182/blood.v88.1.236.236
T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28.
C. Renner (1996)
10.1158/1078-0432.CCR-04-0428
B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression
J. Konishi (2004)
10.1200/JCO.2014.32.15_SUPPL.3005
Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
R. Kefford (2014)
[The clinical significance of the expression of costimulatory molecule PD-L1 in nasopharyngeal carcinoma].
F. Zhang (2008)
10.2174/1381612033392026
Macrophages and the regulation of self-reactive T cells.
D. Munn (2003)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na¨na¨ıve patients with advanced melanoma
M Hersh (2011)
Is herpes zoster a marker for occult or subsequent malignancy?
F. Buntinx (2005)
10.1158/0008-5472.CAN-05-2213
Marrying immunotherapy with chemotherapy: why say IDO?
A. J. Muller (2005)
Varicella-zoster virus: aspects of pathogenesis and host respone to natural infection and varicella
A. M. Arvin (1996)
10.1007/s10637-009-9376-8
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
E. Hersh (2009)
10.1016/j.imbio.2011.07.005
Ipilimumab (Yervoy) and the TGN1412 catastrophe.
T. Bakacs (2012)
10.1038/bjc.2013.645
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
H-B Jie (2013)
10.1158/0008-5472.CAN-12-4100
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Jaikumar Duraiswamy (2013)
10.1158/0008-5472.CAN-12-2384
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.
Sofia Lyford-Pike (2013)
10.1038/icb.2010.121
PD-1 modulates Regulatory T cells and suppresses T cell responses in HCV-associated Lymphoma
L. Ni (2011)
10.1111/cas.12502
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
Kayoko Waki (2014)
10.1200/JCO.2007.25.18_SUPPL.5120
Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)
W. Gerritsen (2007)
10.1007/s00262-006-0266-z
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
J. Nakanishi (2006)
10.1200/JCO.2013.53.0105
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
10.1073/pnas.1533209100
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
Survival and longterm follow-up of the phase I trial of nivolumab
J R Brahmer
10.1158/1078-0432.CCR-04-1469
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Yuichiro Ohigashi (2005)
10.1200/JCO.2014.32.15_SUPPL.5009
Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.
R. Motzer (2014)
10.1200/JCO.2014.32.15_SUPPL.5010
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
A. Amin (2014)
Relationship between the expressions of PD-L1 and tumorinfiltrating lymphocytes in oral squamous cell carcinoma
Y.-A Cho (2011)
Relationship between the expressions of PD - L 1 and tumor - infiltrating lymphocytes in oral squamous cell carcinoma
S.-P. Hong
Loss of T - cell receptor ζ chain and p 56 lck in T - cells infiltrating human renal cell carcinoma
J. H. Finke (1993)
Co - inhibitorymolecules of the B 7 - CD 28 family in the control of T - cell immunity
R. V. Parry (2004)
10.1200/JCO.2013.31.15_SUPPL.8030
Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).
J. Brahmer (2013)
10.1038/modpathol.2010.130
Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma
Mei-Chi Hsu (2010)
10.1038/nrc1586
Immunosuppressive networks in the tumour environment and their therapeutic relevance
W. Zou (2005)
10.1016/J.MOLMED.2003.11.003
IDO and tolerance to tumors.
D. Munn (2004)
10.1016/j.cell.2011.09.024
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Scott Valastyan (2011)
10.1038/ni1029
Priming of naive T cells inside tumors leads to eradication of established tumors
Ping Yu (2004)
10.1200/JCO.2008.16.1927
Phase I/II study of ipilimumab for patients with metastatic melanoma.
J. Weber (2008)
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
J. Finke (1993)
10.1007/s00262-011-1104-5
Dual biological effects of the cytokines interleukin-10 and interferon-γ
C. Wilke (2011)
10.1016/0092-8674(91)90314-O
The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways
B. A. Irving (1991)
10.1146/annurev.immunol.26.021607.090331
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
10.1097/PAS.0000000000000297
Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain
M. Shi (2014)
10.1002/ijc.22703
Expression of B7‐H1 in breast cancer patients is strongly associated with high proliferative Ki‐67‐expressing tumor cells
H. Ghebeh (2007)
10.1038/bjc.2013.13
The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study
S. J. Cotton (2013)
Co-inhibitorymolecules of the B7-CD28 family in the control of T-cell immunity,”Nature
L. Chen (2004)
ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)
(2014)
10.1016/J.YONC.2012.07.009
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
A. Tsao (2012)
Nivolumab (anti- PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial
J. R. Brahmer (2013)
10.1097/JTO.0b013e3181d60fd7
Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer
K. Shimizu (2010)
10.1200/JCO.2014.32.15_SUPPL.8021
Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.
J. Brahmer (2014)
Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patientswith non-small cell lung cancer
E. Garon (2013)
Relationship between the expressions of PD-L1 and tumorinfiltrating lymphocytes in oral squamous cell carcinoma,”Oral
Y.-A. Cho (2011)
10.1016/S0140-6736(14)60958-2
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C. Robert (2014)
10.1200/JCO.2012.30.15_SUPPL.7509
Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).
J. Brahmer (2012)
Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1)
J. Soria (2013)
10.1056/NEJMoa1302369
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
10.1111/j.1600-065X.2008.00662.x
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
B. Fife (2008)
10.1093/annonc/mdt107
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
S. Slovin (2013)
10.1200/JCO.2014.32.15_SUPPL.5011
Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).
T. Powles (2014)
10.1016/j.oraloncology.2011.08.007
Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
Y. Cho (2011)
10.1016/j.athoracsur.2008.10.067
Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms.
E. Ruffini (2009)
10.1615/CRITREVIMMUNOL.V21.I5.10
Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue.
C. Mills (2001)
10.1200/JCO.2013.31.15_SUPPL.3000
A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
R. Herbst (2013)
10.1200/JCO.2012.44.6112
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
A. Ribas (2013)
Phase III randomized clinical trial comparing tremelimumab with standardof-care chemotherapy in patients with advanced melanoma
A. Ribas (2013)
10.1007/s00262-010-0909-y
In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors
C. Berthon (2010)
10.1200/JCO.2010.28.15_SUPPL.4689
Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC).
A. Harzstark (2010)
10.1056/NEJMoa1305133
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naı̈ve patients with advanced melanoma
E. M. Hersh (2011)
10.1200/JCO.2008.19.2435
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
L. Camacho (2009)
10.1182/blood-2010-01-265975
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.
Jang-June Park (2010)
10.1200/JCO.2014.32.15_SUPPL.5012
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.
T. Choueiri (2014)
10.1073/pnas.0830997100
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F. S. Hodi (2003)
10.1200/JCO.2014.32.15_SUPPL.3015
Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.
R. Joseph (2014)
10.1200/JCO.2013.31.15_SUPPL.4505
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).
D. Cho (2013)
Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dosecomparison cohort of a phase 1 trial
C. Robert (2014)
10.1200/jco.2009.27.15_suppl.8071
Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
P. Zatloukal (2009)
10.1016/J.ACTHIS.2006.01.003
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.
C. Wu (2006)
10.1002/lary.21913
The clinical implications of antitumor immunity in head and neck cancer
C. Allen (2012)
10.1158/0008-5472.CAN-08-3529
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
L. Fong (2009)
10.1002/eji.201344421
AID induces intraclonal diversity and genomic damage in CD86+ chronic lymphocytic leukemia cells
M. Huemer (2014)
10.1073/pnas.0915174107
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
M. Curran (2010)
10.1038/nri1349
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
L. Chen (2004)



This paper is referenced by
10.1177/2324709616674316
Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease
Sneha Phadke (2016)
10.24060/2076-3093-2019-9-3-216-222
Опухолевые стволовые клетки мультиформной глиобластомы как потенциальные терапевтические мишени
O. Beylerli (2019)
10.1186/s13045-016-0345-3
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
C. Zelle-Rieser (2016)
10.1016/j.pathol.2016.07.003
Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
L. Satgunaseelan (2016)
10.1038/nmicrobiol.2017.8
Carcinogenesis and therapeutics: the microbiota perspective
Matthew C. B. Tsilimigras (2017)
10.1080/2162402X.2016.1220467
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition
Patricia Kleinpeter (2016)
10.21037/TLCR-20-536
On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer.
P. Correale (2020)
10.1016/bs.acr.2015.10.001
HSP90 and Immune Modulation in Cancer.
M. Graner (2016)
10.1002/med.21478
Potential cardiac risk of immune‐checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects
P. Spallarossa (2018)
10.1016/j.intimp.2017.10.016
Nafamostat mesilate, a serine protease inhibitor, suppresses interferon‐gamma‐induced up‐regulation of programmed cell death ligand 1 in human cancer cells
S. Homma (2018)
10.1016/J.BULCAN.2017.10.012
Cellules souches cancéreuses dans les glioblastomes
T. Virolle (2017)
10.1080/10428194.2020.1751840
Low absolute CD4+ T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma
Y. Gu (2020)
10.1007/s00428-020-02922-5
PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer
N. D’Alessandris (2020)
10.1016/j.jconrel.2018.09.008
Delivering all in one: Antigen‐nanocapsule loaded with dual adjuvant yields superadditive effects by DC‐directed T cell stimulation
David Paßlick (2018)
10.2217/fon-2019-0097
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
S. Qin (2019)
10.3390/vaccines8040616
Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Mohamed A Abd El Aziz (2020)
Semantic Scholar Logo Some data provided by SemanticScholar